All In MedTech

FDA Clearance Tracker · P200015-S011

Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 16, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 16, 2021

Approved

Time to decision

178 days

Received Jun 21, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

The decision

FDA number
P200015-S011
Device name
Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent
Applicant location
Irvine, CA
Received
Jun 21, 2021
Decided
Dec 16, 2021
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P200015

Device type

Every decision under product code NPV

FDA's approval statement

As written in FDA's record.

Approval for the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent. The device is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation as measured by echocardiography who have a native or surgically-repaired right ventricular outflow tract and are clinically indicated for pulmonary valve replacement.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.